Jonathan Allan - 15 Mar 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
GENERAL COUNSEL & CORP SEC
Signature
/s/ Jonathan Allan
Issuer symbol
STOK
Transactions as of
15 Mar 2025
Net transactions value
$0
Form type
4
Filing time
18 Mar 2025, 16:11:54 UTC
Previous filing
11 Dec 2024
Next filing
20 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +7,475 +34% $0.000000 29,776 15 Mar 2025 Direct F1
transaction STOK Common Stock Options Exercise $0 +6,000 +20% $0.000000 35,776 15 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise $0 -7,475 -33% $0.000000 14,950 15 Mar 2025 Common Stock 7,475 Direct F2, F3
transaction STOK Restricted Stock Units Options Exercise $0 -6,000 -25% $0.000000 18,000 15 Mar 2025 Common Stock 6,000 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported total includes an aggregate 825 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.
F4 The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date.